nezastomig

{
  "id": "MLC-T-ONC-015497",
  "term": "nezastomig",
  "field": "Oncology and biomedicine",
  "definition": "A bispecific antibody directed against both the tumor-associated antigen (TAA) prostate-specific membrane antigen (PSMA) and the co-stimulatory T-cell-specific surface glycoprotein CD28, with potential immunostimulating and antineoplastic activities. Upon administration of nezastomig this bispecific antibody binds to both CD28 on cytotoxic T lymphocytes (CTLs) and PSMA found on PSMA-expressing tumor cells. This activates and redirects CTLs to PSMA-expressing tumor cells, which may result in the CTL-mediated cell death of PSMA-expressing tumor cells. PSMA is overexpressed on the surface of metastatic and hormone-refractory prostate cancer cells.",
  "synonyms": [
    "anti-PSMAxCD28 antibody REGN5678",
    "anti-PSMA/anti-CD28 bispecific antibody REGN5678",
    "anti-PSMA/CD28 bispecific antibody REGN5678"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/nezastomig/"
}